An open label phase 3 study of fortigel [ProStrakan] testosterone gel 2% in hypogonadal males.
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics; Registrational
- Acronyms FORTIFY
- Sponsors ProStrakan
- 31 Aug 2018 Biomarkers information updated
- 08 May 2009 Planned number of patients changed from 140 to 149 as reported by ClinicalTrials.gov.
- 08 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.